Oliver Sartor

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

M. Oya, N. Mehra, C. Poehlein, 2023, The Lancet. Oncology.

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.

E. Sokol, O. Smaletz, E. Antonarakis, 2023, European urology oncology.

Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.

M. Sydes, Oliver Sartor, Wanling Xie, 2024, European urology.

Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.

Oliver Sartor, Bernd J. Krause, R. Ghouse, 2024, Cancer.

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).

H. Beltran, M. Matikainen, N. Fossati, 2024, European urology.

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

H. Beltran, M. Taplin, J. Calais, 2024, Cancer.